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ABSTRACT
The small hydrophobic (SH) glycoprotein of human respiratory syncytial virus (RSV) is a transmembrane
protein that is poorly accessible by antibodies on the virion but has an ectodomain (SHe) that is
accessible and expressed on infected cells. The SHe from RSV strain A has been formulated in DPX,
a unique delivery platform containing an adjuvant, and is being evaluated as an RSV vaccine candidate.
The proposed mechanism of protection is the immune-mediated clearance of infected cells rather than
neutralization of the virion. Our phase I clinical trial data clearly showed that vaccination resulted in
robust antibody responses, but it was unclear if these immune responses have any correlation to
immune responses to natural infection with RSV. Therefore, we embarked on this study to examine
these immune responses in older adults with confirmed RSV infection. We compared vaccine-induced
(DPX-RSV(A)) immune responses from participants in a Phase 1 clinical trial to paired acute and
convalescent titers from older adults with symptomatic laboratory-confirmed RSV infection. Serum
samples were tested for anti-SHe IgG titers and the isotypes determined. T cell responses were evaluated
by IFN-γ ELISPOT. Anti-SHe titers were detected in 8 of 42 (19%) in the acute phase and 16 of 42 (38%) of
convalescent serum samples. IgG1, IgG3, and IgA were the prevalent isotypes generated by both
vaccination and infection. Antigen-specific T cell responses were detected in 9 of 16 (56%) of vaccinated
participants. Depletion of CD4+ but not CD8+ T cells abrogated the IFN-γ ELISPOT response supporting
the involvement of CD4+ T cells in the immune response to vaccination. The data showed that an
immune response like that induced by DPX-RSV(A) could be seen in a subset of participants with
confirmed RSV infection. These findings show that older adults with clinically significant infection as
well as vaccinated adults generate a humoral response to SHe. The induction of both SHe-specific
antibody and cellular responses support further clinical development of the DPX-RSV(A) vaccine.
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Respiratory syncytial virus (RSV) is the leading cause of early
childhood bronchiolitis and pneumonia worldwide and
results in significant hospitalizations in infants, the elderly,
and immunocompromised individuals.1–4 There is an increas-
ing recognition of the unmet medical need for an effective
RSV vaccine for older persons.1 To this end, several groups
have predominantly focused their vaccine development efforts
toward targeting the transmembrane fusion (F) protein or
glycoprotein (G) of the two RSV subtypes5-7 and more than
10 are in development for this age group.8 The majority of
these vaccine candidates were designed to potentially function
via antibody-mediated virus neutralization.9 To date, no pro-
phylactic RSV vaccine has been approved for clinical use.
Novel approaches to induce non-neutralizing antibodies
targeting the infected cells rather than the virion itself are
being explored for vaccine development against other intra-
cellular pathogens. For example, targeting the ectodomain of
the matrix protein 2 (M2e) of the influenza A virus has shown
effective protection against influenza A virus infection in pre-
clinical models.10 HIV vaccine candidates that induce non-
neutralizing antibodies acting through antibody-dependent
cellular cytotoxicity (ADCC) have also been reported.11
The small hydrophobic glycoprotein (SH) of RSV is a type
II transmembrane protein that forms pentameric transmem-
brane pores in infected cells.12 It functions as a viral ion
channel13 and might impact viral fusion.14 RSV mutants lack-
ing the SH protein are attenuated in vivo but not in vitro,
indicating that the SH protein is most likely involved in
pathogenesis and interferes with the host immune
response.15,16 In this context the SH protein is known to
inhibit TNF-α signaling and to either enable or inhibit inflam-
masome activation.17–19 Interestingly, SH protein is poorly
accessible to targeted antibodies whereas it is highly expressed
on the surface of infected cells,20 making it a potentially
unique non-neutralizing RSV vaccine candidate. Antibodies
toward the ectodomain of SH (SHe), induced by a SHe pep-
tide fused to a carrier, have been shown to control RSV
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infection in mice and cotton rats.20 These pre-clinical studies
of the candidate SHe-based vaccine demonstrated that the
suppression of viral replication depends on the activation of
Fcγ receptors, in particular, FcγRI and FcγRIII, as well as the
involvement of alveolar macrophages. This immune response
suggests that the likely mechanism of action of viral suppres-
sion is ADCC or antibody-dependent cellular phagocytosis
(ADCP).20 While there are limited data on the anti-SHe
human response, it has been proposed that natural infection
may not induce a strong immune response to SHe in mice
and rats due to its cellular location.20,21 An advantage of
targeting SHe is that it provides an alternative avenue for
immune protection and may be complementary to natural
immunity.
DPXTM is a lipid-in-oil delivery platform that facilitates
antigen delivery to regional lymph nodes and has been
demonstrated to induce robust T cell and B cell responses in
pre-clinical and clinical studies for both cancer and infectious
disease, respectively.22–25 We previously demonstrated in mice
that a novel DPX formulation incorporating the SHe peptide
of group A RSV (DPX-RSV(A)) elicited more robust immune
responses compared to an alum-adjuvanted vaccine.26
Furthermore, a Phase 1 clinical trial in 50–64 year old healthy
adults demonstrated DPX-RSV(A) to be safe and well-
tolerated, and induced robust antigen-specific serum IgG
responses in the DPX-RSV(A) 25-μg (high dose) group that
were sustained for more than a year.27 Binding of clinical trial
participant anti-SHe IgG antibodies to SH-expressing mam-
malian cells was observed, supporting the proposed infected
cell-based mechanism of action in response to DPX-RSV(A).
The objective of this study is to further characterize the
immune response to DPX-RSV(A) of this adult population
in order to compare with the responses of adults with symp-
tomatic laboratory-confirmed RSV infection.
Materials and methods
Human samples
Healthy participants (50–64 years) were randomly allocated to
a two-dose schedule (study day (D) 0, 56) of low or high doses
(10 µg or 25 µg) of DPXTM-RSV(A) (n = 8 low dose, n = 8
high dose) RSV(A)-Alum (n = 8 low dose, n = 8 high dose) on
D0 (placebo on D56), or placebo on D0 and D56. Serum was
collected on D0, D7, D28, D56, D63, D84, and D236; in the
high-dose arm D421 was also collected. PBMCs were collected
on D0, D56, and D84. The study (Clinical Trials Registration
NCT02472548) was undertaken in compliance with Good
Clinical Practice (GCP) guidelines, the Declaration of
Helsinki, and national regulatory requirements and was
approved by the local Institutional Review Board (IRB).
Confirmed RSV-infected participants
Serum samples from RSV-confirmed participants (ages range
58–91) were collected by the University of Rochester at the
time of illness (acute) and 4 to 6 weeks later (convalescent).
RSV infection was confirmed by viral culture or Reverse
Transcription Polymerase Chain Reaction (RT-PCR).
ELISA
Anti-SHeA antibodies from serum samples were detected by
indirect ELISA as described.27 Briefly, 96-well ELISA plates
were coated with SHe strain A antigen and twofold dilutions
of serum were added at a starting dilution of 1:100. Bound
antibodies were detected by anti-human IgG horseradish per-
oxidase detection antibody. Positive response defined as OD
reading twice the assay background.
Flow cytometry
PBMCS from healthy participants (50–64 years) enrolled in Phase
1 clinical trial NCT0247254827 were characterized for various
B cell and T cell subsets.Within the B cell population, we analyzed
plasma cells (CD20−CD27+CD138+CD126+CD38+), exhausted
memory B cells (CD19+CD21lowCD27−), IgM memory B cells
(CD19+CD27+IgMhi), activated memory B cells (CD19+CD21low
CD27+), isotype-switched memory B cells (CD19+CD27+IgG+),
nBregs (CD10−CD5hi), plasmablast (CD19+CD21−CD27+), acti-
vated B cells (CD19+HLA-DR+CD38+), naïve B cells
(CD19+CD21+CD27−) resting memory B cells (CD19+CD21+
CD27+). Within the T cell population, we analyzed CD4+ T cells,
whether there was proliferation as determined by Ki67 expression,
whether they are Th1 or Th2 polarized cells via expression levels of
CXCR3, Tbet, TNF, and IFN-γ for Th1, and CCR4, GATA3, and
IL-4 for Th2, and whether the T cells were naïve, effector, or
memory cells via expression of CD45RA and CCR7. B and
T cells were evaluated by flow cytometry using the following
antibodies; CD19-Alexa Fluor 700 (Clone HIB19), CD10-BV605
(Clone HI10a), CD20-BV786 (Clone 2H7), CD27-BV510 (Clone
L128), CD38-BV650 (Clone HIT2), CD138-PE-CF594 (Clone
MI15), CD21-APC (Clone B-ly4), IgM-BB515 (Clone G20-127),
IgG-PE (Clone G18-145), CD5-APC-Cy7 (Clone UCHT2), HLA-
DR-PerCP-Cy5.5 (Clone G46-6), CD126-BV421 (Clone M5),
CD4-PerCP-Cy5.5 (Clone SK3), T-Bet-PE-CF594 (Clone O4-
46), TNF-PE (Clone MAb11), Ki-67-AF488 (Clone B56),
CD45RA-APC-H7 (Clone HI100), CD3-AF700/CD3-PeCy7
(Clone UCHT1), IFN-γ-APC (B27), IL-4-BV786 (Clone MP4-
25D2), CCR7-BV650 (Clone 3D12), CD194 (CCR4)-BV605
(Clone 1G1), CD183-BV510 (Clone 1 C6/CXCR3), and GATA3-
BV421 (Clone L50-823) obtained from BD Biosciences or
BioLegend. Data were acquired on the BD FACS Celesta (BD
Biosciences) and was analyzed by FlowJo Software (v10)
Antibody isotyping
Anti-SHe specific antibody isotyping was performed by flow
cytometry analysis. For each sample, 107 polystyrene beads
(Bangs Laboratory) were coated with 100 ug SHe dimer.20
Human serum was incubated with beads coated with SHe-
antigen for 2 h, then a cocktail of fluorescent-labeled antibo-
dies toward human IgM, IgD, IgG1, IgG2, IgG3, IgG4, IgA,
IgE were used including: Mouse anti-human IgG1 Fc-PE
(Clone HP6001) (Southern Biotech), Mouse anti-human
IgG2-FITC (Clone HP-6014) (Sigma), Mouse anti-human
IgG3-Hinge PE (Clone HP6050) (Southern Biotech), Mouse
anti-human IgG4-pFc’AF647 (Clone HP6023) (Southern
Biotech), Mouse anti-human IgA-FITC (Clone M2A) (EMD
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Millipore), Mouse anti-human IgE BV650 (Clone G7-26) (BD
Bioscience), Mouse anti-human IgD BV605 (Clone 1A6-2)
(BD Bioscience), and Mouse anti-human IgM BV421 (Clone
G20-127) (BD Bioscience). Bound antibodies were detected by
flow cytometry on a BD FACS Celesta (BD Biosciences) and
UltraComp eBeads (Invitrogen) were used for compensation
control. Data were analyzed by FlowJo Software (v10).
IFN- γ ELISPOT assay
IFN-γ ELISPOT was performed on SHe peptide stimulated
PBMCs28 using the Human IFN-γ ELISPOT Kit (CTL). Briefly,
freshly thawed PBMCs were incubated at 300,000 cells per well
with CTL-Test medium and were stimulated or not with SHe
peptide (50 μg/ml) or Cell Stimulation Cocktail (Invitrogen)
(positive control) for 22 ± 2 h at 37ºC and 5% CO2. After over-
night culture, plates were developed to detect spot forming units
(SFU). For CD4+ or CD8+ T cell depletion ELISPOTs, selected cell
types were depleted prior to ELISPOT using a magnetic bead
positive selection kit (StemCell Technologies).
Results
Isotype profile of DPX-RSV(A) induced SHe-specific
antibodies
We first characterized the isotype and subclass profile of
antibodies to DPX-RSV(A) vaccination using serum samples
of the Phase 1 clinical trial (NCT02472548), in which two
vaccine doses were used (Step 1, 10 µg, n = 8 or Step 2, 25 µg,
n = 8). The majority (11/16) of the DPX-RSV(A) responsive
participants demonstrated an increase in the IgG1, IgG3, or
IgA anti-SHe subclasses. More specifically, of the 11 DPX-
RSV(A) vaccinated participants in which antibodies were
detected posttreatment 10 (91%) generated IgG1, 6 (55%)
generated IgG3, 4 (36%) generated IgA, while only 2 (18%)
generated IgG2 isotypes. The increase in IgG1 and/or IgG3
isotypes demonstrated a trend in a time-dependent manner
and correlated with the previous ELISA results (representative
examples in Figure 1A,B; Table 1). In contrast, the serum
samples from the DPX-RSV(A) non-responsive participants
as well as the majority of the participants in the RSV(A)-Alum
and placebo arms did not demonstrate a similar increase in
any anti-SHe antibody isotypes (representative example,
Figure 1C; Table 1). Of the RSV-Alum group examined
(n = 9 out of 16), 2 out of 9 (22%) generated IgG1 and 1
out of 9 (11%) generated IgE isotypes but no IgG3 or any
other of the other isotypes examined (IgG2, IgG4, IgA, IgD,
IgM) (Table 1).
Cellular immune response to DPX-RSV(A) vaccination
includes T cell involvement
To evaluate the immune-phenotype associated with the DPX-
RSV(A) vaccine immunization, longitudinally collected
PBMC samples (D0, D56, D84) from participants vaccinated
with DPX-RSV(A) (Step 1, 10 µg, n = 8 or Step 2, 25 µg,
n = 8), RSV(A)-Alum (Step 1, 10 µg, n = 8 or Step 2, 25 µg,
n = 8); or placebo (Step 1, n = 4; Step 2, n = 4) were evaluated
by flow cytometry. Comprehensive analyses of B cell pheno-
types including the plasma cells, exhausted memory cells,
activated memory B cells, natural B regulatory cells, IgM+
memory B cells, IgG+ memory B cells, naïve B cells, plasma-
blasts, resting memory B cells and activated B cells revealed
that none of these B cell sub-populations were altered between
different treatment groups or over time within a specific
vaccine group (data not shown).
Similarly, within the T cell population, the presence of
CD4+ and CD8+ phenotypes, their respective proliferation
status (Ki67 expression) as well as the Th1/Th2 subpopula-
tions were assessed along with the naïve, effector or memory
cell phenotypes. While no significant difference was observed
in the total CD4+ cells (data not shown), participants immu-
nized with RSV(A)-Alum (Step 2, 25 µg dose) demonstrated
a significant increase in the proliferating CD4+ T cells (CD4+-
Ki67+) by D56 and D84 compared to respective D0 values
(Figure 2A). Both RSV(A)-Alum (Step 2, 25 µg dose) partici-
pants and DPX-RSV(A) (Step 2, 25 µg dose) participants had
a significant increase in CD4+IFN-γ+ T cells (Figure 2B)
suggesting that the vaccination with the SHe antigen may
elicit an active cellular immune response.
DPX-RSV(A) vaccination induces a CD4+ T cell response
To further characterize the functional cellular response to SHe
vaccination, the longitudinally collected PBMC samples (D0,
D56, D84) from participants immunized with DPX-RSV(A)
(Step 1, 10 µg, n = 8 or Step 2, 25 µg, n = 8), RSV(A)-Alum
(Step 1, 10 µg, n = 8 or Step 2, 25 µg, n = 8), or placebo (Step
1, n = 4; Step 2, n = 4) were assayed for IFN-γ secretion using
an ELISPOT assay. Of note, only DPX-RSV(A) vaccinated
participants demonstrated a trend toward positive IFN-γ
response (Figure 3A). The DPX-RSV(A) high-dose (Step 2,
25 µg dose) subgroup response was found to be significantly
higher than the other study arms with a mean of 377 SFU per
106 PBMC on D84 (p = .002). Moreover, the IFN-γ ELISPOT
responses correlate (p = .0124) with DPX-RSV(A) participants
demonstrating high antibody titers by ELISA (Table 1).
To further understand the respective contribution of CD4+
and CD8+ T cells in the IFN-γ response to SHe(A) stimulation,
we depleted either CD4+ or CD8+ T cells in PBMCs of DPX-RSV
(A) vaccinated participants and assessed IFN-γ ELISPOT
response (representative example, Figure 3B-C). The IFN-γ
ELISPOT response was abrogated upon depletion of CD4+
T cells but not that of CD8+ T cells suggesting that the IFN-γ
response upon DPX-RSV(A) vaccination is primarily driven by
CD4+ T cell (Figure 3C).We also observed positive IL-4 ELISPOT
response in two representatives DPX-RSV(A) vaccinated partici-
pants that generated an IFN-γ response (data not shown).
Antibody responses to SHe can be detected during
natural RSV infection in older adults
With data to support the generation of anti-SHe antibodies in
response to DPX-RSV(A) vaccination, we were interested to
determine whether anti-SHe antibodies are also generated during
the course of natural infection in the older adult population (aged
58–91). For this, paired acute and convalescent serum samples
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from older adults with symptomatic confirmed RSV infection
were obtained from the University of Rochester and screened
for anti-SHe IgG titers. ELISA analysis indicated the presence of
anti-SHe IgG in only 9 out of 42 (21%) acute serum samples
(Table 2). Detection of anti-SHe in convalescent serum did not
correlate with clinical variables27 or RSV strain type but was more
likely to occur in subjects with detectable anti-SHe in acute
samples (p = .13). Sixteen out of 42 (38%) of the convalescent
serum samples from RSV-infected adults tested positive for the
anti-SHe titers, nine of which (56%) were also positive in the
corresponding acute sample (Table 2). None of the samples
were positive in acute but negative in convalescent. Stratifying
this analyses on the basis of the infecting RSV strain (A vs B), we
further observed that only strain A infections were characterized
by a detectable rise (≥2x) in the anti-SHe titers above the corre-
sponding acute sample (Table 2). Five out of the fifteen (33%)
confirmed RSV A infections resulted in an anti-SHe response, as
detected by ELISA. In comparison, all subjects had detectable
F and G antibody at baseline with most demonstrating robust
increases to both antigens with infection (Table 2).
Isotype characterization of serum samples from these natu-
rally infected adult participants revealed that similar to DPX-
RSV(A) vaccination, RSV infection also primarily generates
IgG1, IgG3, and IgA isotypes which further corresponds to
the anti- SHe ELISA titers (Figure 4A-B). Analysis of the
University of Rochester samples (Table 3) also shows that
about half of the patients have anti-SHe antibodies in the
acute sample of either one or a combination of these three
isotypes (IgG1, IgG3, IgA) and that the infection led to an
increase from acute to convalescent in IgG1 (34%), IgG3
(25%), or IgA (16%). Moreover, we observed that the ELISA
response was associated with either an increase in, or acute
infection levels of, IgG1 (Table 3).
Discussion
Enhanced understanding of the role of the SH protein in RSV
infection and the mechanism of DPX-RSV(A) vaccination is
important to validate the utility of incorporating the SHe(A)
peptides in the DPX formulation. Our previous clinical work
highlighted the safety and efficacy of DPX-RSV(A) compared to
both placebo and an alum-based vaccine. It also demonstrated
that vaccination with DPX-RSV(A) leads to a robust and highly




Figure 1. Characterization of anti-SHe(A) response induced by DPX-RSV(A). Subjects in clinical trial NCT02472548 received two doses of low dose (10 μg SHe(A)
antigen, n = 8) or high dose (25 μg SHe(A) antigen, n = 8) in DPX-RSV(A). Anti-SHe(A) responses toward SHe(A) were detected in serum by ELISA (line graphs). Anti-
SHe(A) isotyping was performed by flow-cytometry. Subject 030 (A), Subject 037 (B), and Subject 026 (C), are representative subjects from DPX-RSV(A) high dose
cohort. Bar graphs represent mean florescent intensity (MFI) of anti-human IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE and IgM antibodies bound to SHe(A) labeled beads
for the background (Bkgd), D0 (0), D28 (28), D56 (56), and D84 (84).
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Table 1. Relative change in SHe(A)-specific antibody isotypes in all Cl1204 trial DPX-RSV(A) (n = 16) and representative Alum-RSV(A) (n = 9 of 16) or Placebo (n = 5
of 8) treated subjects from D0 to D84 with corresponding ELISA and ELISPOT results.
Isotypea
Subject Treatment Group IgG1 IgG2 IgG3 IgG4 IgA IgE IgD IgM ELISAb ELISPOTc
1 DPX1-Step 1 ++ *
5 DPX2-Step 1
7 DPX3-Step 1 ++ ++ +++ +++
11 DPX4-Step 1 + + +
14 DPX5-Step 1 + ++ +
15 DPX6-Step 1
18 DPX7-Step 1 +
19 DPX8-Step 1 + + *
24 DPX1-Step 2 ++ +
26 DPX2-Step 2
30 DPX3-Step 2 + + +++ + ++ +++
31 DPX4-Step 2 ++ ++ + *
32 DPX5-Step 2 ++ ++ ++ *
35 DPX6-Step 2 + +++
37 DPX7-Step 2 +++ + +++ ++ +++ +++















†Isotyping legend: Relative change D0-D84: >2-fold but <10-fold (+), ≥ 10-fold (++), ≥ 100-fold (+++). Preexisting response: >10-fold higher than background at D0
(gray shading).
††ELISA legend: Relative change D0-D84 in OD (450 nm): <0.4 (*), >0.4 (+), >0.8 (++), >1.6 (+++). Preexisting response: >0.2 OD (450 nm) at SD0 (gray shading).




Figure 2. Percentage of key CD4+ T cell populations in PBMCs. Percentage Ki67+ CD4+ T cells (A), and IFN-γ+ CD4+ T cells (B) of total live PBMCs, of Cl1204 subjects
on D0, D56, and D84 postvaccination. Live cells were gated based on forward scatter and side scatter. Data shown as the average of eight subjects per Alum or DPX
treatment group, four subjects in placebo groups, ± SEM. *p < .05, ***p < .001, two-way ANOVA with Tukey’s posttest. Light gray * indicates significance for Alum
Step 2 samples compared to D0. Dark gray* indicates significance for DPX-RSV(A) Step 2 samples compared to D0.
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participants.27 The trial also established, in vitro, a significant
increase in binding of anti-SHe IgG antibodies to SH-expressing
human cells exposed to sera of DPX-RSV(A)-vaccinated
participants.27 In this work, we performed a detailed character-
ization of the DPX-RSV(A) elicited an immune response in the
context of severe disease in the elderly population to further
understand its mechanism of action and potential clinical utility
as a novel vaccine candidate against RSV in this population.
Antibodies of various isotypes that bind to the same target can
elicit different immune responses. Varied vaccine formulations
differ in their ability to generate a repertoire of isotypes for specific
antigenic targets. Here we further characterized the immune
responses of participants immunized with DPX-RSV(A) vaccine
and demonstrate that the robust response consists of IgG1, IgG3,
and IgA isotypes (Table 1). In contrast, the comparator RSV(A)-
alum formulationmainly induced an IgG1 response, and in a very
small proportion of participants (n = 2/9 participants evaluated).
Thus, these data show that DPX-RSV(A) vaccination elicits
a wider variety of anti-SHe isotypes, including IgG3 which is
considered a robust mediator of effector T cell functions and
ADCP or ADCC against invading pathogens.29,30 As expected,
we observed a time-dependent increase in these isotypes which
correlates with an increase in total anti-SHe antibody titers.
Induction of the IgA isotype has been a challenge and goal in
vaccine development as IgA plays a role in mucosal immunity
and is the first line of defense against pathogens entering by this
route.31 The fact that the DPX-RSV(A) vaccine immunization is
also associated with an increase in anti-SHe IgA isotypes is
therefore noteworthy since the upper respiratory tract is the
initial site of RSV infection. The generation of high-affinity
IgA isotypes is known to be mediated by a T cell-dependent
pathway.31 These findings highlight the unique mechanism of
action of the DPX-RSV(A) approach and pave the way for future
functional and mechanistic studies in this direction.
Interestingly, we observed that the DPX-RSV(A) vaccina-
tion also induced CD4+ T cell-dependent IFN-γ responses
that tended to be correlated with a strong increase in IgG3
(Table 1). These preliminary findings support the premise
that the DPX-RSV(A) vaccine induces the Th1 antigen-
specific CD4+ T cell response which sustains the development
and maintenance of memory B cell population. The fact that
we also observed positive IL-4 ELISPOT response in two
representatives DPX-RSV(A) treated participants, further sup-
ports the stimulation of B cells by the DPX-RSV(A) vaccina-
tion platform. IL-4 is associated with Th2 polarized CD4 + T
cells involved in humoral immunity. The ability for this plat-
form to generate both a Th1 as well as a Th2 response may
prove to be an advantage over traditional alum-based vac-
cines. Typically, alum-based vaccines elicit a Th2 response.32
Of note, the production of IL-4 in response to natural RSV
infection or vaccination has been implicated in the reduction
of RSV-specific cytotoxic T-cells in vivo.33
RSV is known to modulate the host immune system to evade
themechanisms for the development ofmemory responsemaking
persons susceptible to reinfections throughout life.34 Natural RSV
infection is also known to involve the production of virus-
neutralizing antibodies and T cell-specific host immunity.35
Vaccine candidates mimicking and amplifying this natural
immune response might hold promising clinical utility. Most
adults have high levels of RSV-neutralizing antibodies due to
multiple RSV infections. Yet a prior assessment of five standar-
dized sera samples from humans failed to demonstrate anti-SHe
antibodies.20 However, a potential limitation of this analysis may
be the fact that these samples were not collected at the time of
infection but were randomly collected samples that had anti-F and
-G antibodies, indicating prior RSV infection. Testing pre- and
post-infection human serum may, therefore, provide more accu-
rate information about the acute increase in SHe-specific antibo-
dies generated, yet does not explore the potential duration of these
responses. Here we report that nine out of 42 (21%) of the
participants of the University of Rochester cohort had anti-SHe
IgG as detected by ELISA. Five out of 15 (33%) of participants
with confirmed RSV Strain A infection generated anti-SHe IgG at
the convalescent stage that is at least twofold above the
a b
c
Figure 3. DPX-RSV(A) induces SHe(A) specific CD4 + T cells. Subjects treated with DPX-RSV(A) (Step 1, n = 8; Step 2, n = 8), RSV(A)-Alum (Step 1, n = 8; Step 2, n = 8),
or placebo (Step 1, n = 4; Step 2, n = 4). IFN-γ ELISPOT response performed using PBMC samples (A). Representative IFN-ɣ ELISPOT (B). Representative example of
IFN-ɣ ELISPOT performed using PBMCs whole or CD8+ or CD4+ depleted (C). Responses to SHe(A) stimulation shown, background responses were >51 SFU per 10^6
PBMC. Statistics by 2way ANOVA and Tukey’s multiple comparisons test.
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corresponding acute samples. Notably, none of the Strain B RSV
infected subjects in the Rochester cohort had a response to SHe by
ELISA.
Similar antibody responses have been observed for the
ectodomain of the influenza A M2 protein, which is highly
reminiscent to the RSV SH protein including bearing a very
small ectodomain. The low levels of serum antibodies directed
against the M2 ectodomain (M2e) that can be detected in
human sera have illustrated that the anti-M2e antibody
responses upon natural infections are weak and/or
transient.36,37 Interestingly, the frequency and level of anti-
M2e serum antibodies is very low in children and young
adults but increases with age.37 In adults aged >40 years up
to 50% had detectable preexisting anti-M2e serum antibodies.
This observation indicates that to acquire detectable levels of
serum anti-M2e antibodies reoccurring influenza infections
are required. As RSV reinfects throughout life it would be
interesting to test if the level and frequency of preexisting
anti-SHe antibodies increases with age. It was demonstrated
that natural infection with 2009 pandemic H1N1 influenza
A virus elicited anti-M2e antibody responses in 47% of
patients. Analogous to our SHe results, these responses were
clearly more robust in patients with preexisting anti-M2e
antibodies.37 This observation suggests that vaccine-induced
antibody responses to these small and poorly immunogenic
viral proteins could potentially be boosted by infection. In
contrast to natural influenza infections vaccines based on M2e
(M2e-VLP + QS21 and M2e-flagelin) were able to elicit anti-
M2e antibody responses in almost all (95-97%)
volunteers.38,39 However, in contrast to DPX- RSV(A) vacci-
nation those antibody responses clearly dropped over time.
Isotype analysis of the immune response during measles
virus infection showed that compared to the convalescent
samples, the acute samples were characterized by an initial
Table 2. Anti-SHe(A), anti-F, and anti-G titers detected in subjects with confirmed RSV infection at acute and convalescent stages from the University of Rochester
and their corresponding strain.
Anti-SHe(A) Titres



































S1 A + + + + + + + 2 + + 2.5 + + 1.5
S2 A + + + + + + + 8 + + 5.5 + + 5.5
S6 A + + + + - + + 4 + + 4.5 + + 3
S9 A - + + + + + + 7 + + 5.5 + + 5
S10 A - + + + + + + 4 + + 4 + + 4
S14 A - + + - + + + 5 + + 6.5 + + 6
S17 A - - - - - + + 4 + + 4.5 + + 2
S18 A - - - - - + + 6 + + 4 + + 3.5
S19 A - - - - - + + 8 + + 7 + + 7
S23 A - - - - - + + 6 + + 4.5 + + 3.5
S26 A - - - - - + + 5 + + 6 + + 5.5
S28 A - - - - - + + 5 + + 5 + + 6.4
S36 A - - - - - + + 3 + + 1 + + 1.5
S39 A - - - - - + + 5 + + 3.5 + + 2.5
S41 A - - - - - + + 6 + + 3.5 + + 4
S5 B + + + + - + + 3 + + 2 + + 3
S8 B + + + - - + + 3 + + 0.68 + + 3
S21 B - - - - - + + 4 + + 1.5 + + 2.5
S22 B - - - - - + + 8 + + 4.5 + + 4
S24 B - - - - - + + 4 + + 3.5 + + 4.5
S25 B - - - - - + + 6 + + 3.5 + + 5.06
S27 B - - - - - + + 4 + + 3 + + 3.5
S29 B - - - - - + + 0 + + 1.5 + + 2.5
S30 B - - - - - + + 2 + + 4 + + 3.5
S31 B - - - - - + + 3 + + 3 + + 4
S34 B - - - - - + + 4 + + 2 + + 2.5
S37 B - - - - - + + 3 + + 2 + + 3
S40 B - - - - - + + 2 + + 3 + + 2
S3 NA + + + + + + + 2 + + 1.5 + + 3
S4 NA + + + + +
S7 NA + + + - - + + 3 + + 0 + + 0
S11 NA + + + + - + + 1 + + 2 + + 1
S12 NA - + + + + + + 5 + + 5.68 + + 6
S13 NA - + + + + + + 2 + + 3 + + 3
S15 NA - + + - + + + 3 + + 2 + + 3
S16 NA - + + - - + + 4 + + 3.5 + + 2
S20 NA - - - - - + + 2 + + 2 + + 2
S32 NA - - - - - + + 2 + + 1.5 + + 2
S33 NA - - - - - + + 3 + + 0.5 + + 3
S35 NA - - - - - + + 2 + + 1 + + 2
S38 NA - - - - - + + 1 + + 2.5 + + 1
S42 NA - - - - - + + 1 + + 0 + + -1
RSV strain confirmed by PCR and anti-SHe(A), anti-F, and anti-G titers determined by ELISA. NA – RSV Strain unknown. Anti-SHe(A) positive response was defined as
an optical density (OD) reading twice the background at 1:100 dilution. Anti- SHe(A) titers detected in the acute and convalescent phase of RSV-infected subjects
with 2 and 4-fold rise in titers above background in convalescent phase and 2 times above the respective acute phase. GA and GB indicate anti-G responses that
are specific to RSV type A and B, respectively.
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surge of IgG1 response followed by IgG2, IgG3, and IgG4.40
Interestingly, the percentage of IgG2 and IgG3 dropped during
the memory phase, meanwhile IgG1 and IgG4 remained
detectable for years after infection.40 Our data from similar
isotype characterization of paired serum samples from RSV-
infected subjects demonstrate that the natural RSV infection
generated an isotype repertoire of anti-SHe antibodies very
similar to that induced by the DPX-RSV(A) vaccination with
IgG1, IgG3, and IgA being the primary isotypes identified
(Figure 4A-B, Table 3). While we could not differentiate the
preexisting levels from infection-induced changes, this analysis





































































































Figure 4. Representative ELISA data of anti-SHe detection in confirmed RSV(A) infection patient serum and anti-SHeA antibody isotyping. Serum was assayed for SHe
antibodies by ELISA in doubling dilutions from 1:100 (A). Positive response defined as OD reading twice the assay background at 1:100 dilution. Isotyping of anti-SHe
(A) antibodies (B). Acute serum sample (light gray), convalescent serum sample (black).
Table 3. Relative change in SHeA-specific serum antibody isotypes of natural infection subjects from acute to convalescent with corresponding ELISA results and
confirmation by PCR of RSV infection type.
Isotypea
Subject ID RSV Strain Type IgG1 IgG2 IgG3 IgG4 IgA IgE IgD IgM ELISAb
S6 A












S30 B + +
S31 B + +
S34 B
S37 B ++ +
S40 B
S3 NA + + + +
S4 NA ++ + ++
S7 NA
S11 NA ++ + +
S12 NA ++ + +
S13 NA + ++





S35 NA + +
S38 NA
S42 NA
aIsotyping legend: Relative change from acute to convalescent: >2-fold but <10-fold (+), ≥10-fold (++), ≥100-fold (+++). Pre
existing response: >10-fold higher than the background in acute (gray shading).
bELISA legend: Relative change from acute to convalescent by OD (450 nm): <0.4 (+), >0.4 (++), >0.8 (+++). Preexisting response: >0.2 OD (450 nm) in acute (gray
shading).
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cohort. In conclusion, we find that natural RSV infection leads
to the production of similar isotypes as those generated by
DPXTM-RSV(A) with a clear trend toward IgG1, IgG3, and
IgA. Although baseline SHe antibody levels and responses to
natural infection were less frequent than those to F and G RSV
antigens (Table 2), it is worth noting that natural immunity is
both transient and incomplete.
The proposedmechanism of action of DPX-RSV(A) is that: 1,
DPX facilitates active uptake of antigens delivered in DPX at the
site of injection; 2, antigen that travels to the regional lymph
node where CD4+ T cells are activated to support and maintain
B cells; and 3, induces a robust SHe immune response (Figure
5A). We speculate that SHe-specific antibodies limit infection by
clearance of RSV-infected airway epithelial cells. Specifically,
antibodies access the RSV-infected airway epithelia and bind to
SH on the infected cell surface. This binding stimulates phago-
cytosis by alveolar macrophages, thereby limiting viral infection
in the lung (Figure 5B). Supportively, in addition to strong anti-
body titers, we have observed that antibodies generated by this
platform can bind to mammalian cells expressing SH, mimick-
ing the context of natural binding conditions.27
While future studies must confirm these preliminary find-
ings in large randomized cohorts, our data demonstrates that
a unique DPX-RSV(A) formulation targeting the SH ectodo-
main of RSV Strain A produces a robust immune response
characterized by an increase in anti-SHe IgG1, IgG3, and IgA
antibodies as well as a CD4+ T cell-dependent IFN-γ response.
When compared to natural acute and convalescent samples,
the immune response to DPX-RSV(A) is at least equivalent to
the response induced by natural RSV infection. This suggests
that the vaccine can generate or enhance preexisting humoral
immunity to the SHe antigen, to a similar extent as natural
infection. One limitation of this study was that only acute and
convalescent serum samples were available from this natural
infection cohort. Therefore, our analysis was limited to con-
temporaneous infection assessment and we could not examine
sustained response, nor could we examine T cell response.
Interestingly, a panel of human RSV reference serum from the
National Institutes of Health (NIH) was previously screened20
and while the immune response to the F and G protein was
widespread, the response to SHe was low suggesting that there
is a limited natural sustained response to SHe. This contrasts
with what we observed with DPX-RSV(A) vaccination. As
such, opportunity exists to augment the natural immunity
by prophylactic vaccination with DPX-RSV(A). Importantly,
this study did not examine the protective effects of the vac-
cine. Future studies should investigate whether preexisting
immunity to SHe can limit re-infection and if so, whether
prophylactic treatment with DPX-RSV(A) would be effective.
In conclusion, DPX-RSV(A) induced a humoral immune
response that mimics that of the natural RSV infection and
may prove to be a robust platform for eliciting durable
protection.
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